TimothyMLestingiMD

PubMed

• 2 citations
  An Attempt to Quantitate "Value" In Medical Oncologic Therapy.
  Christie Hancock, Linda Green, Timothy M. Lestingi, Jacob D. Bitran> ;Cureus. 2018 Jun 14
• 7 citations
  Copper deficiency mimicking myelodysplastic syndrome.
  Neil Dalal, Arthur L. Hooberman, Rachel Mariani, Ronald Sirota, Timothy M. Lestingi> ;Clinical Case Reports. 2015 May 1
• 16 citations
  Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
  Chadi Nabhan, Anand Patel, Dana Villines, Kathy Tolzien, Susan K. Kelby, Timothy M. Lestingi> ;Clinical Genitourinary Cancer. 2014 Feb 1
• 12 citations
  Role of Sorafenib in Overcoming Resistance of Chemotherapy-Failure Castration-Resistant Prostate Cancer
  Andrew Meyer, Peter Cygan, Kathy Tolzien, Angel G. Galvez, Jacob D. Bitran, Timothy M. Lestingi, Chadi Nabhan> ;Clinical Genitourinary Cancer. 2014 Apr 1
• 46 citations
  A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
  Kimberly Kruczek, Megan Ratterman, Kathy Tolzien, Suela Sulo, Timothy M. Lestingi, Chadi Nabhan> ;British Journal of Cancer. 2013 Oct 1
• 15 citations
  Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostat...
  Chadi Nabhan, Dana Villines, Tina V. Valdez, Kathy Tolzien, Timothy M. Lestingi, Jacob D. Bitran, Susan M. Christner, Merrill J. Egorin, Jan H. Beumer> ;British Journal of Cancer. 2012 Aug 7
• Phase I study of imatinib mesylate (IM) and sorafenib (S) in patients (pts) with refractory castration-resistant prostate cancer (CRPC).
  Nabhan C, Villines D, Valdez TV, Tolzien K, Lestingi TM, Bitran JD, Susan CM, Egorin MJ, Beumer JH> ;J. Clin. Oncol.. 2012-02-10
• Overcoming chemotherapy resistance in patients (pts) with chemotherapy-failure, castration-resistant prostate cancer (CRPC) with sorafenib.
  Nabhan C, Cygan PH, Meyer A, Tolzien K, Galvez AG, Lestingi TM, Bitran JD> ;J. Clin. Oncol.. 2012-02-10
• Effect of lenalidomide (LEN) on biochemical responses and clinical benefit (CB) as a single agent in chemotherapy-naive castration-resistant prostate cancer (CRPC).
  Nabhan C, Patel A, Villines D, Tolzien K, Kelby SK, Lestingi TM> ;J. Clin. Oncol.. 2012-02-10
• A phase II study evaluating the toxicity and efficacy of single-agent temsorilmus (TEM) in chemotherapy-naive castration-resistant prostate cancer (CRPC): First report...
  Nabhan C, Kruczek K, Tolzien K, Galvez AG, Lestingi TM> ;J. Clin. Oncol.. 2012-02-10
• A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration -...
  Chadi Nabhan, Andrew Meyer, Kathy Tolzien, Jacob D. Bitran, Timothy M. Lestingi> ;Avicenna Journal of Medicine. 2011 Jul 1
• 36 citations
  Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial
  Chadi Nabhan, Timothy M. Lestingi, Angel G. Galvez, Kathy Tolzien, Susan K. Kelby, Dean Tsarwhas, Steven Newman, Jacob D. Bitran> ;Urology. 2009 Sep 1
• Maintenance GM-CSF in patients with castration-resistant prostate cancer (CRPC) who maximized their response to chemotherapy.
  Bitran JD, Tolzien K, Lestingi TM, Nabhan C> ;J. Clin. Oncol.. 2009-05-20
• Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC).
  Nabhan C, Tolzien K, Lestingi TM, Galvez A, Bitran JD> ;J. Clin. Oncol.. 2009-05-20
• A pilot study investigating maintenance sargramostim in patients with androgen-independent prostate cancer (AIPC) who have maximized their response to chemotherapy: pr...
  Bitran JD, Tolzien K, Lestingi TM, Nabhan C> ;J. Clin. Oncol.. 2008-05-20
• A phase II study with single agent erlotinib in chemotherapy-naïve androgen independent prostate cancer (AIPC).
  Lestingi TM, Tolzien K, Galvez A, Kelby S, Bitran JD, Nabhan C> ;J. Clin. Oncol.. 2008-05-20
• 67 citations
  Combination of Chemotherapy With Interleukin-2 and Interferon Alfa for the Treatment of Metastatic Melanoma
  Jon M. Richards, Danielle Gale, Nilesh Mehta, Timothy Lestingi> ;Journal of Clinical Oncology. 1999 Feb 1
• 6 citations
  Intermittent Androgen Suppression as a Treatment for Prostate Cancer: A Review
  Andrew M. Evens, Timothy M. Lestingi, Jacob D. Bitran> ;The Oncologist. 1998 Dec 1
• 145 citations
  Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
  Elora Gupta, Rosemarie Mick, Jacqueline Ramírez, Xiaolin Wang, Timothy M. Lestingi, Everett E. Vokes, Mark J. Ratain> ;Journal of Clinical Oncology. 1997 Apr 1
• 2 citations
  Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
  Rosemarie Mick, Everett E. Vokes, Timothy M. Lestingi, Winifred Gray-Stern, Gini F. Fleming, Richard L. Schilsky, Mark J. Ratain> ;Clinical Pharmacology and Therapeutics. 1996 Mar 1
• 401 citations
  Metabolic Fate of Irinotecan in Humans: Correlation of Glucuronidation with Diarrhea
  Elora Gupta, Timothy M. Lestingi, Rosemarie Mick, Jacqueline Ramírez, Everett E. Vokes, Mark J. Ratain> ;Cancer Research. 1994 Jul 15
• 46 citations
  Philadelphia chromosome-positive acute lymphoblastic leukemia.
  Timothy M. Lestingi, Arthur L. Hooberman> ;Hematology/oncology Clinics of North America. 1993 Feb 1
• Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions.
  Vogelzang, N. J., Lestingi, T. M., Sudakoff, G., Kradjian, S. A.> ;Hum Gene Ther. 1994 Nov
• A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable...
  Clark, J. I., Kuzel, T. M., Lestingi, T. M., Fisher, S. G., Sorokin, P., Martone, B., Viola, M., Sosman, J. A.> ;Ann Oncol. 2002 Apr
• Join now to see all